Table 1.
Characterization of study population by race-gender group.
| Variables1 | Units | TotalPop | AAF2 | AAM2 | CF2 | CM2 |
|---|---|---|---|---|---|---|
| n=200 | n=40 | n=40 | n=60 | n=60 | ||
| Age | Years | 63 ± 9 | 60 ± 11 | 60 ± 7 | 65 ± 9 | 64 ± 9 |
| Smoker (Ever/Never) | 113/87 | 13/27 | 27/13 | 31/29 | 42/18 | |
| Diabetes (Yes/No) | 70/130 | 18/22 | 15/25 | 19/41 | 18/42 | |
| Hypertension (Yes/No) | 154/46 | 35/5 | 34/6 | 44/16 | 41/19 | |
| Height | Inches | 67 ± 4 | 65 ± 3 | 69 ± 3 | 65 ± 3 | 70 ± 3 |
| Weight | pounds | 198 ± 44 | 197 ± 54 | 201 ± 36 | 183 ± 43 | 214 ± 38 |
| BMI | kg/m2 | 31 ± 6 | 33 ± 8 | 30 ± 5 | 31 ± 7 | 30 ± 5 |
| HDL | mg/dL | 48 ± 16 | 56 ±13 | 43 ±12 | 51 ± 16 | 40 ± 13 |
| LDL | mg/dL | 107 ± 36 | 123 ± 37 | 98 ± 30 | 116 ± 40 | 95 ± 29 |
| Triglycerides | mg/dL | 149 ± 97 | 119 ± 53 | 126 ± 113 | 162 ± 73 | 171 ± 122 |
| TotalChol | mg/dL | 185 ± 45 | 203 ± 43 | 165 ± 34 | 202 ± 48 | 168 ± 39 |
| Statin Use (Yes/No) | 121/79 | 19/21 | 29/11 | 30/30 | 43/17 | |
| HDL group (Low/Normal) | 76/120 | 5/34 | 18/22 | 14/44 | 39/20 | |
| LDL group (Elevated/Normal) | 156/41 | 25/14 | 35/5 | 43/15 | 53/7 | |
| Trig group (Abnormal/Normal)3 | 43/63 | 3/19 | 5/9 | 19/20 | 16/15 | |
| TotalChol group (Abnormal/Normal)3 | 69/37 | 21/9 | 7/8 | 29/10 | 12/10 | |
| Atherosclerosis (Yes/No) | 96/104 | 10/30 | 25/15 | 21/39 | 40/20 |
1
Variables: Age, Height, Weight, Body Mass Index (BMI), Total Cholesterol, HDL cholesterol, and LDL cholesterol are expressed as means ± SD. Variables: Smoker, Diabetes, Hypertension, Statin Use, HDL group, LDL group, Trig group, and TotalChol group were expressed as ratios.
2
AAF=African American Female, AAM=African American Male, CF=Caucasian Female, and CM=Caucasian Male.
3
Subjects receiving statin therapy were not included in the summary statistics for these variables